Literature DB >> 10693999

Parents' preferences for outcomes associated with childhood vaccinations.

M Kuppermann1, R F Nease, L M Ackerson, S B Black, H R Shinefield, T A Lieu.   

Abstract

BACKGROUND: The number of shots in the childhood immunization schedule has been increasing and is likely to continue to increase in the coming years. Consideration of the psychologic costs of multiple injections, adverse events and vaccine-preventable disease is therefore growing in importance.
METHODS: We assessed parent preferences, using both the time tradeoff (i.e. amount of parent time willing to trade) and willingness-to-pay (i.e. dollars willing to pay) metrics, for possible outcomes of vaccination among 206 parents of infants receiving care at Kaiser, Northern California Region. We also explored the relationship between preferences and subject characteristics.
RESULTS: In general the amount of time subjects were willing to give up and the quantity of money they were willing to spend to avoid an outcome increased with the severity of the outcome. Preferences for our six main outcomes of interest all differed from one another (P < 0.0001, Tukey's multiple comparisons procedure). Rank correlation coefficients between time tradeoff and willingness-to-pay values for the six main outcomes ranged from 0.42 to 0.52 (all P < 0.004). Subject characteristics, including education, income, race/ethnicity and the child's birth order, did not explain the variation in parent preferences.
CONCLUSIONS: In general subjects were willing to give up more money or time to avoid less desired outcomes. They were willing to give up only very small amounts of their own life expectancy or money to avoid minor, temporary outcomes (e.g. moderate fussiness, fever and pain) whereas they were willing to forego substantial lengths of their life or amounts of money to avoid a major, permanent outcome (i.e. permanent disability). Nonetheless much variation surfaced in the amount of time (or money) subjects were willing to trade to avoid outcomes. If this variation represents true differences in preferences, guideline developers must consider the role of individual parent preferences in decisions concerning vaccination.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10693999     DOI: 10.1097/00006454-200002000-00010

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  12 in total

1.  Using Monte Carlo simulation to determine combination vaccine price distributions for childhood diseases.

Authors:  Sheldon H Jacobson; Edward C Sewell
Journal:  Health Care Manag Sci       Date:  2002-04

2.  Pricing strategies for combination pediatric vaccines and their impact on revenue: Pediarix or Pentacel?

Authors:  Matthew J Robbins; Sheldon H Jacobson; Edward C Sewell
Journal:  Health Care Manag Sci       Date:  2010-03

Review 3.  A descriptive review on methods to prioritize outcomes in a health care context.

Authors:  Inger M Janssen; Ansgar Gerhardus; Milly A Schröer-Günther; Fülöp Scheibler
Journal:  Health Expect       Date:  2014-08-25       Impact factor: 3.377

Review 4.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

5.  Emotions and scope effects in the monetary valuation of health.

Authors:  María V Avilés Blanco; Raúl Brey; Jorge Araña; José Luis Pinto Prades
Journal:  Eur J Health Econ       Date:  2017-03-24

6.  Engineering the economic value of two pediatric combination vaccines.

Authors:  Sheldon H Jacobson; Edward C Sewell; Tamana Karnani
Journal:  Health Care Manag Sci       Date:  2005-02

7.  The distribution over time of costs and social net benefits for pertussis immunization programs.

Authors:  Dorota Zdanowska Girard
Journal:  Int J Health Care Finance Econ       Date:  2009-03-18

8.  Valuation of symptomatic hepatitis a in adults: estimates based on time trade-off and willingness-to-pay measurement.

Authors:  R Jake Jacobs; Ronald J Moleski; Allen S Meyerhoff
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

9.  Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule.

Authors:  Francis Fagnani; Camille Le Fur; Isabelle Durand; Michel Gibergy
Journal:  Eur J Health Econ       Date:  2004-06

10.  Health-state valuations for pertussis: methods for valuing short-term health states.

Authors:  Grace M Lee; Joshua A Salomon; Charles W LeBaron; Tracy A Lieu
Journal:  Health Qual Life Outcomes       Date:  2005-03-21       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.